Once weekly subcutaneous administration of erythropoietin in haemodialysis patient.
Twenty-five anaemic patients of End Stage Renal Disease (ESRD) on maintenance haemodialysis at the Kidney Centre were studied. Recombinant human erythropoietin (EPO) 50-units/kg body weight was given once a week subcutaneously to see the response to therapy. In 21 cases haemoglobin increased significantly from 7.5 to 9.5 g/dl and haematocrit from 23 to 30.5 l/l with success rate of 84% and marked improvement in their quality to life. Once a week subcutaneous administration of erythropoietin is convenient and cost effective in reversing renal anaemia with minimal complications.
Hussain
R
R
Kidney Centre, Jinnah Postgraduate Medical Centre, Karachi.
Naqvi
S A
SA
D000328:Adult; D000740:Anemia / Q000209:etiology / Q000517:prevention & control*; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D008297:Male; D011994:Recombinant Proteins; D006435:Renal Dialysis
D011994:Recombinant Proteins; D004921:Erythropoietin